Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Stock Has Average Price Target of $10.00

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has earned an average recommendation of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $10.00.

A number of equities research analysts have weighed in on the company. Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Wall Street Zen upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, August 3rd.

Hedge Funds Weigh In On Autolus Therapeutics

Large investors have recently added to or reduced their stakes in the business. QRG Capital Management Inc. boosted its holdings in Autolus Therapeutics by 67.7% during the 2nd quarter. QRG Capital Management Inc. now owns 18,325 shares of the company’s stock valued at $29,000 after acquiring an additional 7,400 shares during the period. Alphabet Inc. purchased a new position in Autolus Therapeutics in the 2nd quarter worth approximately $1,117,000. Syncona Portfolio Ltd bought a new stake in Autolus Therapeutics in the second quarter valued at approximately $26,625,152. Hennion & Walsh Asset Management Inc. lifted its position in Autolus Therapeutics by 2.5% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock valued at $722,000 after purchasing an additional 11,197 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Autolus Therapeutics by 115.6% in the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock worth $25,000 after purchasing an additional 8,309 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Trading Down 2.9%

Shares of Autolus Therapeutics stock opened at $1.85 on Friday. The company has a 50 day simple moving average of $2.00 and a two-hundred day simple moving average of $1.70. The firm has a market cap of $493.73 million, a PE ratio of -1.75 and a beta of 2.10. Autolus Therapeutics has a 1 year low of $1.18 and a 1 year high of $2.58. The company has a debt-to-equity ratio of 1.04, a current ratio of 4.89 and a quick ratio of 4.40.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. The firm had revenue of $45.69 million for the quarter, compared to analysts’ expectations of $38.56 million. Analysts expect that Autolus Therapeutics will post -0.75 earnings per share for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc (NASDAQ: AUTL) is a biopharmaceutical company developing and commercializing programmed T-cell therapies for cancer and other serious diseases. The company uses genetic engineering to create CAR T-cell products designed to recognize and eliminate cancer cells while improving control, persistence and safety compared with earlier-generation cell therapies.

Autolus’ lead product, obecabtagene autoleucel, also known as obe-cel and marketed in the United States as AUCATZYL, is a CD19-directed autologous CAR T-cell therapy.